Which is better, Tysabri or Ocrevus?: A Comprehensive Comparison for MS Patients
•
5 min read
For individuals with multiple sclerosis (MS), deciding between high-efficacy disease-modifying therapies like Tysabri (natalizumab) and Ocrevus (ocrelizumab) can be a complex and highly personal choice. While both are powerful infusion therapies designed to manage the disease, they operate through distinct mechanisms and carry different risk profiles, making the question of which is better, Tysabri or Ocrevus, depend entirely on individual patient factors.
